AMD drug collaboration

MacuCLEAR and Mystic Pharmaceuticals are to collaborate on MacuCLEAR’s upcoming Phase I/II trials of MC 1101 for the treatment and prevention of progression of dry age-related macular degeneration (AMD).

Mystic Pharmaceuticals produces the VeriDoser targeted, individual-use eyedropper drug delivery system, which MacuCLEAR will use as a platform to deliver doses of MC 1101.

MC 1101, which performed well in preclinical tests, has received FDA Fast Track status, allowing acceleration through the trial and approval process.